NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NA
Post# of 369
(Total Views: 327)
Posted On: 07/12/2021 3:40:50 PM
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug
CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening conditions. According to WPD, GBM is one of the most aggressive and deadly types of brain cancer, and many patients have almost no meaningful treatment options. The fast track designation creates an accelerated pathway for CNS Pharmaceuticals to gain approval for Berubicin, a move that offers significant potential benefits for WPD because the company has the rights to produce and sell the drug candidate in 29 countries, primarily in Europe. Most recently, CNSP began enrolling patients in its upcoming study of Berubicin.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening conditions. According to WPD, GBM is one of the most aggressive and deadly types of brain cancer, and many patients have almost no meaningful treatment options. The fast track designation creates an accelerated pathway for CNS Pharmaceuticals to gain approval for Berubicin, a move that offers significant potential benefits for WPD because the company has the rights to produce and sell the drug candidate in 29 countries, primarily in Europe. Most recently, CNSP began enrolling patients in its upcoming study of Berubicin.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)